id: NEW:antiepileptic_drug_treatment_aws_to_NEW:alcohol_withdrawal_seizure_incidence
name: Antiepileptic Drug Treatment for Alcohol Withdrawal Syndrome â†’ Alcohol Withdrawal
  Seizure Incidence
from_node:
  node_id: NEW:antiepileptic_drug_treatment_aws
  node_name: Antiepileptic Drug Treatment for Alcohol Withdrawal Syndrome
to_node:
  node_id: NEW:alcohol_withdrawal_seizure_incidence
  node_name: Alcohol Withdrawal Seizure Incidence
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Patients with moderate to severe alcohol withdrawal syndrome are admitted
  to inpatient settings and prescribed antiepileptic drugs (AEDs) such as carbamazepine,
  valproic acid, or other anticonvulsants'
- 'Step 2: AEDs are intended to modulate neuronal excitability by blocking voltage-gated
  sodium channels, enhancing GABAergic inhibition, or reducing glutamatergic transmission
  to prevent seizure activity'
- 'Step 3: Despite theoretical mechanisms, systematic evidence shows AEDs provide
  no significant benefit over placebo or standard treatments in reducing seizure incidence
  during AWS (RR = 1.0, indicating no effect)'
- 'Step 4: The lack of demonstrated efficacy means that AED treatment does not reduce
  alcohol withdrawal seizure incidence compared to alternative approaches'
evidence:
  quality_rating: A
  n_studies: 26
  primary_citation: 'Jenny Rojo-Mira et al. 2021. Efficacy and Safety of Anticonvulsants
    for the Inpatient Treatment of Alcohol Withdrawal Syndrome: A Systematic Review
    and Meta-analysis. Alcohol and Alcoholism.'
  supporting_citations: []
description: 'This systematic review and meta-analysis of 26 randomized controlled
  trials (n=1709) found no significant benefit of antiepileptic drug treatment in
  preventing seizures during moderate to severe alcohol withdrawal syndrome. The pooled
  relative risk was 1.0 (95% CI: 0.76-1.33), indicating AEDs neither increase nor
  decrease seizure incidence compared to other treatments or placebo. The evidence
  quality was rated as moderate using GRADE methodology, leading to a weak recommendation
  against routine AED use for AWS unless indicated for comorbid conditions.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 1.0
    type: relative_risk
    ci_lower: 0.76
    ci_upper: 1.33
  p_value: null
  sample_size: 1709
moderators:
- name: Comparator type
  direction: weakens
  strength: weak
  description: When compared specifically to placebo, AEDs showed similar null effect
    (RR = 0.95, CI 0.57-1.57), confirming no seizure prevention benefit
- name: AWS severity
  direction: weakens
  strength: moderate
  description: Studies focused on moderate to severe AWS; outpatient and unspecified
    severity cases were excluded, potentially limiting generalizability
